Compare Nokia Corp (NOK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs BIO-TECHNE Corp — how do they compare? Nokia Corp trades at $9.5 (market cap $51.87B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Nokia Corp is far larger — about 4.6× BIO-TECHNE Corp's market cap, and Nokia Corp pays the higher dividend (1.79%). Which is the better fit depends on your goals.
| NOK | TECH | |
|---|---|---|
Market Cap | $51.87B | $11.24B |
Sector | Technology | Health |
52-Week High | $16.83 | $72.29 |
52-Week Low | $4.10 | $43.31 |
Enterprise Value | $49.82B | $11.32B |
Dividend Yield | 1.79% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.37, down 0.53% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue for 2025 was $19.89B, with a net income margin of 3.47%. Analyst consensus is 60% buy, supported by strong cash flow from operations of $2.07B in 2025 and a focus on AI and cloud infrastructure growth.
Outlook is cautiously optimistic due to AI demand boosting earnings, but risks include telecom spending volatility and high P/E of 67.5. The stock offers growth potential from AI networking, yet investors face margin pressures and competitive threats in the telecom equipment sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
